Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial

Study Questions:

What is the efficacy and tolerability of AMG145, a human monoclonal antibody to plasma protein convertase subtilisin/kexin type 9 (PCSK9), in statin-intolerant patients with a documented history of muscle-related adverse effects?